메뉴 건너뛰기




Volumn 32, Issue 11, 2002, Pages 554-563

Prevention of autoimmune attack and disease progression in multiple sclerosis: Current therapies and future prospects

Author keywords

Antibodies; Autoimmunity; Drug therapy; Experimental autoimmune encephalomyelitis; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; LENERCEPT; LIGAND; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PLACEBO;

EID: 0036400960     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-5994.2002.00269.x     Document Type: Review
Times cited : (28)

References (60)
  • 1
    • 0033812142 scopus 로고    scopus 로고
    • The occurrence of autoimmune diseases in patients with multiple sclerosis and their families
    • Henderson RD, Bain CJ, Pender MP. The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J Clin Neurosci 2000; 7: 434-7.
    • (2000) J Clin Neurosci , vol.7 , pp. 434-437
    • Henderson, R.D.1    Bain, C.J.2    Pender, M.P.3
  • 2
    • 0032495663 scopus 로고    scopus 로고
    • Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis
    • Pender MP. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet 1998; 351: 978-81.
    • (1998) Lancet , vol.351 , pp. 978-981
    • Pender, M.P.1
  • 3
    • 0031789948 scopus 로고    scopus 로고
    • Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis
    • Sadatipour BT, Greer JM, Pender MP. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998; 44: 980-3.
    • (1998) Ann Neurol , vol.44 , pp. 980-983
    • Sadatipour, B.T.1    Greer, J.M.2    Pender, M.P.3
  • 4
    • 0034676548 scopus 로고    scopus 로고
    • Relapses and progression of disability in multiple sclerosis
    • Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-8.
    • (2000) N Engl J Med , vol.343 , pp. 1430-1438
    • Confavreux, C.1    Vukusic, S.2    Moreau, T.3    Adeleine, P.4
  • 5
    • 0026496706 scopus 로고
    • Relapsing-remitting multiple sclerosis: Sequential enhanced MR imaging v clinical findings in determining disease activity
    • Barkhof F, Scheltens P, Frequin STFM, Nauta JJ, Tas MW, Falk J et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging v clinical findings in determining disease activity. Am J Roentgenol 1992; 159: 1041-7.
    • (1992) Am J Roentgenol , vol.159 , pp. 1041-1047
    • Barkhof, F.1    Scheltens, P.2    Frequin, S.T.F.M.3    Nauta, J.J.4    Tas, M.W.5    Falk, J.6
  • 7
    • 0032796747 scopus 로고    scopus 로고
    • Axonal pathology in multiple sclerosis: Relationship to neurologic disability
    • Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999; 12: 295-302.
    • (1999) Curr Opin Neurol , vol.12 , pp. 295-302
    • Trapp, B.D.1    Ransohoff, R.2    Rudick, R.3
  • 8
    • 0035175051 scopus 로고    scopus 로고
    • Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis
    • Leist TP, Gobbini MI, Frank JA, McFarland HF. Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol 2001; 58: 57-60.
    • (2001) Arch Neurol , vol.58 , pp. 57-60
    • Leist, T.P.1    Gobbini, M.I.2    Frank, J.A.3    McFarland, H.F.4
  • 10
    • 0033546980 scopus 로고    scopus 로고
    • Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H
    • Paolillo A, Coles AJ, Molyneux PD, Gawne-Cain M, MacManus D, Barker GJ et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999; 53: 751-7.
    • (1999) Neurology , vol.53 , pp. 751-757
    • Paolillo, A.1    Coles, A.J.2    Molyneux, P.D.3    Gawne-Cain, M.4    MacManus, D.5    Barker, G.J.6
  • 11
    • 0033552391 scopus 로고    scopus 로고
    • Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis
    • Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354: 1691-5.
    • (1999) Lancet , vol.354 , pp. 1691-1695
    • Coles, A.J.1    Wing, M.2    Smith, S.3    Coraddu, F.4    Greer, S.5    Taylor, C.6
  • 13
    • 0028723892 scopus 로고
    • A brief history of the use of interferons as treatment of multiple sclerosis
    • Jacobs L, Johnson KP. A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol 1994; 51: 1245-52.
    • (1994) Arch Neurol , vol.51 , pp. 1245-1252
    • Jacobs, L.1    Johnson, K.P.2
  • 14
    • 0027418515 scopus 로고
    • Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
    • IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
    • (1993) Neurology , vol.43 , pp. 655-661
  • 15
    • 0027521002 scopus 로고
    • Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
    • Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-7.
    • (1993) Neurology , vol.43 , pp. 662-667
    • Paty, D.W.1    Li, D.K.B.2
  • 16
    • 0008678962 scopus 로고    scopus 로고
    • Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
    • The Multiple Sclerosis Collaborative Research Group
    • Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. The Multiple Sclerosis Collaborative Research Group. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
    • (1996) Ann Neurol , vol.39 , pp. 285-294
    • Jacobs, L.D.1    Cookfair, D.L.2    Rudick, R.A.3    Herndon, R.M.4    Richert, J.R.5    Salazar, A.M.6
  • 17
    • 0035954361 scopus 로고    scopus 로고
    • PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
    • The PRISMS Study Group, the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-36.
    • (2001) Neurology , vol.56 , pp. 1628-1636
  • 18
    • 0034727059 scopus 로고    scopus 로고
    • Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
    • Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al., the CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.
    • (2000) N Engl J Med , vol.343 , pp. 898-904
    • Jacobs, L.D.1    Beck, R.W.2    Simon, J.H.3    Kinkel, R.P.4    Brownscheidle, C.M.5    Murray, T.J.6
  • 19
    • 0035912520 scopus 로고    scopus 로고
    • Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study
    • Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O et al., the Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82.
    • (2001) Lancet , vol.357 , pp. 1576-1582
    • Comi, G.1    Filippi, M.2    Barkhof, F.3    Durelli, L.4    Edan, G.5    Fernandez, O.6
  • 20
    • 0033961721 scopus 로고    scopus 로고
    • IFN-beta differentially regulates CD40-induced cytokine secretion by human dendritic cells
    • McRae BL, Beilfuss BA, van Seventer GA. IFN-beta differentially regulates CD40-induced cytokine secretion by human dendritic cells. J Immunol 2000; 164: 23-8.
    • (2000) J Immunol , vol.164 , pp. 23-28
    • McRae, B.L.1    Beilfuss, B.A.2    Van Seventer, G.A.3
  • 21
    • 0032494792 scopus 로고    scopus 로고
    • Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis
    • European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7.
    • (1998) Lancet , vol.352 , pp. 1491-1497
  • 22
    • 0000784055 scopus 로고    scopus 로고
    • Interferon beta-1b in secondary progressive MS: Clinical and MRI results of a 3-year randomized controlled trial
    • Goodkin DE, North American Study Group. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology 2000; 54: 2352.
    • (2000) Neurology , vol.54 , pp. 2352
    • Goodkin, D.E.1
  • 23
    • 0035849496 scopus 로고    scopus 로고
    • Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results
    • SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-504.
    • (2001) Neurology , vol.56 , pp. 1496-1504
  • 24
    • 0031676732 scopus 로고    scopus 로고
    • Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b
    • Bramanti P, Sessa E, Rifici C, D'Aleo G, Floridia D, Di Bella P et al. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. Neurology 1998; 51: 1720-3.
    • (1998) Neurology , vol.51 , pp. 1720-1723
    • Bramanti, P.1    Sessa, E.2    Rifici, C.3    D'Aleo, G.4    Floridia, D.5    Di Bella, P.6
  • 25
    • 0035912535 scopus 로고    scopus 로고
    • Preventing multiple sclerosis?
    • Ebers GC. Preventing multiple sclerosis? Lancet 2001; 357: 1547.
    • (2001) Lancet , vol.357 , pp. 1547
    • Ebers, G.C.1
  • 26
    • 0033153391 scopus 로고    scopus 로고
    • Inhibition of B cell receptor-mediated apoptosis by IFN
    • Su L, David M. Inhibition of B cell receptor-mediated apoptosis by IFN. J Immunol 1999; 162: 6317-21.
    • (1999) J Immunol , vol.162 , pp. 6317-6321
    • Su, L.1    David, M.2
  • 27
    • 0034912060 scopus 로고    scopus 로고
    • The use of interferon beta at the time of initial diagnosis of multiple sclerosis
    • Pender MP. The use of interferon beta at the time of initial diagnosis of multiple sclerosis. J Clin Neurosci 2001; 8: 381-2.
    • (2001) J Clin Neurosci , vol.8 , pp. 381-382
    • Pender, M.P.1
  • 28
    • 0027976744 scopus 로고
    • Clinical toxicity of the interferons
    • Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 1994; 10: 115-50.
    • (1994) Drug Saf , vol.10 , pp. 115-150
    • Vial, T.1    Descotes, J.2
  • 30
    • 0034124639 scopus 로고    scopus 로고
    • Autoimmune hypothyroidism associated with interferon beta-1b treatment in two patients with multiple sclerosis
    • McDonald ND, Pender MP. Autoimmune hypothyroidism associated with interferon beta-1b treatment in two patients with multiple sclerosis. Aust NZ J Med 2000; 30: 278-9.
    • (2000) Aust NZ J Med , vol.30 , pp. 278-279
    • McDonald, N.D.1    Pender, M.P.2
  • 31
    • 0015103005 scopus 로고
    • Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide
    • Teitelbaum D, Meshorer A, Hirshfeld T, Amon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971; 1: 242-8.
    • (1971) Eur J Immunol , vol.1 , pp. 242-248
    • Teitelbaum, D.1    Meshorer, A.2    Hirshfeld, T.3    Amon, R.4    Sela, M.5
  • 32
    • 0029082566 scopus 로고
    • Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial
    • Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al., the Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-76.
    • (1995) Neurology , vol.45 , pp. 1268-1276
    • Johnson, K.P.1    Brooks, B.R.2    Cohen, J.A.3    Ford, C.C.4    Goldstein, J.5    Lisak, R.P.6
  • 33
    • 6844254570 scopus 로고    scopus 로고
    • Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
    • Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al., the Copolymer 1 Multiple Sclerosis Study Group. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50: 701-8.
    • (1998) Neurology , vol.50 , pp. 701-708
    • Johnson, K.P.1    Brooks, B.R.2    Cohen, J.A.3    Ford, C.C.4    Goldstein, J.5    Lisak, R.P.6
  • 34
    • 0033842848 scopus 로고    scopus 로고
    • Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
    • Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP et al., the Copolymer 1 Multiple Sclerosis Study Group. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000; 6: 255-66.
    • (2000) Mult Scler , vol.6 , pp. 255-266
    • Johnson, K.P.1    Brooks, B.R.2    Ford, C.C.3    Goodman, A.4    Guarnaccia, J.5    Lisak, R.P.6
  • 36
    • 0035957307 scopus 로고    scopus 로고
    • Mechanisms of action of glatiramer acetate in multiple sclerosis
    • Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001; 56: 702-8.
    • (2001) Neurology , vol.56 , pp. 702-708
    • Neuhaus, O.1    Farina, C.2    Wekerle, H.3    Hohlfeld, R.4
  • 37
    • 8044242916 scopus 로고    scopus 로고
    • Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome
    • Millefiorini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997; 244: 153-9.
    • (1997) J Neurol , vol.244 , pp. 153-159
    • Millefiorini, E.1    Gasperini, C.2    Pozzilli, C.3    D'Andrea, F.4    Bastianello, S.5    Trojano, M.6
  • 38
    • 0000793892 scopus 로고    scopus 로고
    • Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, randomised, observer-blind phase III trial: Clinical results and three-year follow-up
    • Hartung HP, Gonsette RE, the MIMS Study Group. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomised, observer-blind phase III trial: clinical results and three-year follow-up. Neurology 1999; 52: A290.
    • (1999) Neurology , vol.52
    • Hartung, H.P.1    Gonsette, R.E.2
  • 39
    • 0000793893 scopus 로고    scopus 로고
    • Mitoxantrone in progressive multiple sclerosis: MRI results of the European phase III trial
    • Krapf H, Morrissey SP, Zenker O, Zwingers T, Gonsette R, Hartung HP et al., the MIMS Study Group. Mitoxantrone in progressive multiple sclerosis: MRI results of the European phase III trial. Neurology 1999; 52: A495.
    • (1999) Neurology , vol.52
    • Krapf, H.1    Morrissey, S.P.2    Zenker, O.3    Zwingers, T.4    Gonsette, R.5    Hartung, H.P.6
  • 40
    • 0027504007 scopus 로고
    • Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults
    • Aviles A, Arevila N, Diaz Maqueo JC, Gomez T, Garcia R, Nambo MJ. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. Leuk Lymphoma 1993; 11: 275-9.
    • (1993) Leuk Lymphoma , vol.11 , pp. 275-279
    • Aviles, A.1    Arevila, N.2    Diaz Maqueo, J.C.3    Gomez, T.4    Garcia, R.5    Nambo, M.J.6
  • 44
    • 0025967752 scopus 로고
    • The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis
    • The Canadian Cooperative Multiple Sclerosis Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441-6.
    • (1991) Lancet , vol.337 , pp. 441-446
  • 45
    • 0027196941 scopus 로고
    • Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group
    • Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43: 910-18.
    • (1993) Neurology , vol.43 , pp. 910-918
    • Weiner, H.L.1    Mackin, G.A.2    Orav, E.J.3    Hafler, D.A.4    Dawson, D.M.5    LaPierre, Y.6
  • 46
    • 0023194967 scopus 로고
    • A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1: Clinical effects
    • Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1: clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511-16.
    • (1987) J Neurol Neurosurg Psychiatry , vol.50 , pp. 511-516
    • Milligan, N.M.1    Newcombe, R.2    Compston, D.A.3
  • 48
    • 0031057970 scopus 로고    scopus 로고
    • Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
    • Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B, the Austrian Immunoglobulin in MS Study Group. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997; 349: 589-93.
    • (1997) Lancet , vol.349 , pp. 589-593
    • Fazekas, F.1    Deisenhammer, F.2    Strasser-Fuchs, S.3    Nahler, G.4    Mamoli, B.5
  • 49
    • 0030799818 scopus 로고    scopus 로고
    • Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: Further analysis of the Austrian Immunoglobulin in MS study
    • Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B, the Austrian Immunoglobulin in MS Study Group. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analysis of the Austrian Immunoglobulin in MS study. Mult Scler 1997; 3: 137-42.
    • (1997) Mult Scler , vol.3 , pp. 137-142
    • Fazekas, F.1    Deisenhammer, F.2    Strasser-Fuchs, S.3    Nahler, G.4    Mamoli, B.5
  • 51
    • 0034093120 scopus 로고    scopus 로고
    • Autologous stem cell transplantation in progressive multiple sclerosis - An interim analysis of efficacy
    • Fassas A, Anagnostopoulous A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V et al. Autologous stem cell transplantation in progressive multiple sclerosis - an interim analysis of efficacy. J Clin Immunol 2000; 20: 24-30.
    • (2000) J Clin Immunol , vol.20 , pp. 24-30
    • Fassas, A.1    Anagnostopoulous, A.2    Kazis, A.3    Kapinas, K.4    Sakellari, I.5    Kimiskidis, V.6
  • 52
    • 0033786776 scopus 로고    scopus 로고
    • Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
    • Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6: 1167-75.
    • (2000) Nat Med , vol.6 , pp. 1167-1175
    • Bielekova, B.1    Goodwin, B.2    Richert, N.3    Cortese, I.4    Kondo, T.5    Afshar, G.6
  • 53
    • 0033791462 scopus 로고    scopus 로고
    • Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
    • Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P et al., the Altered Peptide Ligand in Relapsing MS Study Group. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med 2000; 6: 1176-82.
    • (2000) Nat Med , vol.6 , pp. 1176-1182
    • Kappos, L.1    Comi, G.2    Panitch, H.3    Oger, J.4    Antel, J.5    Conlon, P.6
  • 55
    • 0033546663 scopus 로고    scopus 로고
    • The effect of anti-α4 integrin antibody on brain lesion activity in MS
    • Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP et al., the UK Antegren Study Group. The effect of anti-α4 integrin antibody on brain lesion activity in MS. Neurology 1999; 53: 466-72.
    • (1999) Neurology , vol.53 , pp. 466-472
    • Tubridy, N.1    Behan, P.O.2    Capildeo, R.3    Chaudhuri, A.4    Forbes, R.5    Hawkins, C.P.6
  • 57
    • 0035157681 scopus 로고    scopus 로고
    • Apoptosis of inflammatory cells in immune control of the nervous system: Role of glia
    • Pender MP, Rist MJ. Apoptosis of inflammatory cells in immune control of the nervous system: role of glia. GLIA 2001; 36: 137-44.
    • (2001) GLIA , vol.36 , pp. 137-144
    • Pender, M.P.1    Rist, M.J.2
  • 58
    • 0033546665 scopus 로고    scopus 로고
    • TNF neutralization in MS
    • The Lenercept Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS. Neurology 1999; 53: 457-65.
    • (1999) Neurology , vol.53 , pp. 457-465
  • 59
    • 0342906187 scopus 로고    scopus 로고
    • Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
    • Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-17.
    • (2000) Ann Neurol , vol.47 , pp. 707-717
    • Lucchinetti, C.1    Bruck, W.2    Parisi, J.3    Scheithauer, B.4    Rodriguez, M.5    Lassmann, H.6
  • 60
    • 0033850863 scopus 로고    scopus 로고
    • B cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis: Roles of B cell CD95, CD95L and Bcl-2 expression
    • White CA, Nguyen KB, Pender MP. B cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis: roles of B cell CD95, CD95L and Bcl-2 expression. J Autoimmun 2000; 14: 195-204.
    • (2000) J Autoimmun , vol.14 , pp. 195-204
    • White, C.A.1    Nguyen, K.B.2    Pender, M.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.